Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2018, Article ID 8713020, 4 pages
https://doi.org/10.1155/2018/8713020
Case Report

Protracted Clonal Trajectory of a JAK2 V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia

1Cancer Molecular Diagnostics, St. James’s Hospital, Dublin 8, Ireland
2Department of Haematology, Beaumont Hospital, Dublin 9, Ireland

Correspondence should be addressed to Stephen E. Langabeer; ei.semajts@reebagnals

Received 27 February 2018; Accepted 31 March 2018; Published 9 May 2018

Academic Editor: Sudhir Tauro

Copyright © 2018 Stephen E. Langabeer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. J. Campbell, E. J. Baxter, P. A. Beer et al., “Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation,” Blood, vol. 108, no. 10, pp. 3548–3555, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Theocharides, M. Boissinot, F. Girodon et al., “Leukemic blasts in transformed JAK2 V617F-positive myeloproliferative disorders are frequently negative for the JAK2 V617F mutation,” Blood, vol. 110, no. 1, pp. 375–379, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. S. E. Langabeer, K. Haslam, and E. Elhassadi, “The mutant CALR allele burden in essential thrombocythemia at transformation to acute myeloid leukemia,” Blood Cells, Molecules and Diseases, vol. 65, pp. 66-67, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. C. A. Ortmann, D. G. Kent, J. Nangalia et al., “Effect of mutation order on myeloproliferative neoplasms,” New England Journal of Medicine, vol. 372, no. 7, pp. 601–612, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Chabannon, M. Bost, and D. Hollard, “A case of polycythemia vera occurring in a patient with acute non-lymphoblastic leukemia (ANLL) in long-term first complete remission,” Leukemia, vol. 8, no. 7, pp. 1243-1244, 1994. View at Google Scholar
  6. A. R. Walker, P. G. Rothberg, and J. L. Liesveld, “A case of JAK2 positive essential thrombocythemia 16.5 years after autologous marrow transplantation for AML,” Bone Marrow Transplantation, vol. 39, no. 11, pp. 725-726, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Antonioli, P. Guglielmelli, G. Poli, V. Santini, A. Bosi, and A. M. Vannucchi, “Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2 V617F clonal dominance,” Blood, vol. 110, no. 13, pp. 4620-4621, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Belotti, E. Doni, E. Elli, V. Rossi, P. Pioltelli, and E. M. Pogliani, “Development of polycythemia vera after chemotherapy-induced remission of acute myeloid leukemia: a case report,” Acta Haematologica, vol. 126, no. 1, pp. 52-53, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Girsberger, A. Karow, P. Lundberg et al., “JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report,” Acta Haematologica, vol. 129, no. 1, pp. 23–25, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Haslam, K. M. Molloy, E. Conneally, and S. E. Langabeer, “Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms,” Clinical Chemistry and Laboratory Medicine, vol. 52, no. 3, pp. e29–e31, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Verger, E. Rattarittamrong, G. Letort, E. Raffoux, B. Cassinat, and J. J. Kiladjian, “Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone,” Leukemia and Lymphoma, vol. 58, no. 3, pp. 749–751, 2017. View at Publisher · View at Google Scholar · View at Scopus
  12. A. M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Pardanani, and A. Tefferi, “Clinical correlates of JAK2 V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal,” Leukemia, vol. 22, no. 7, pp. 1299–1307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. C. A. Portell, M. A. Sekeres, H. J. Rogers, and R. V. Tiu, “De novo polycythemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone,” British Journal of Haematology, vol. 157, no. 2, pp. 266-267, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Sato, H. Itonaga, M. Taguchi et al., “Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm,” International Journal of Hematology, 2018, In press. View at Publisher · View at Google Scholar
  15. S. Schnittger, U. Bacher, W. Kern, T. Haferlach, and C. Haferlach, “JAK2 V617F as a progression marker in CMPD and as a cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases,” Leukemia, vol. 21, no. 8, pp. 1843–1845, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. J. E. Hidlago-López, R. Kanagal-Shamanna, L. J. Medeiros et al., “Morphologic and molecular characteristics of de novo AML with JAK2 V617F mutation,” Journal of the National Comprehensive Cancer Network, vol. 15, no. 6, pp. 790–796, 2017. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Nielsen, S. E. Bojesen, B. G. Nordestgaard, K. F. Kofoed, and H. S. Birgens, “JAK2 V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate,” Haematologica, vol. 99, no. 9, pp. 1448–1455, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. T. McKerrell, N. Park, J. Chi et al., “JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics,” Blood Advances, vol. 1, no. 14, pp. 968–971, 2017. View at Publisher · View at Google Scholar
  19. C. S. Hourigan, R. P. Gale, N. J. Gormley, G. J. Ossenkoppele, and R. B. Walter, “Measurable residual disease testing in acute myeloid leukemia,” Leukemia, vol. 31, no. 7, pp. 1482–1490, 2017. View at Publisher · View at Google Scholar · View at Scopus